Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 62 от 222

Набира участници Фаза 1

A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors

Advance Solid Tumors

This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.

Начало: 13.11.2025 Край: 31.03.2030 Възраст: от 18 г. Лечение

Australia, United States Kivu Bioscience Inc. NCT07229313

Набира участници Фаза 2

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

Idiopathic Pulmonary Fibrosis

This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3 months of treatment and will also look at changes in certain markers related to lung health. Participants are put into two groups randomly, which means by chance. One group receives the study medicine, and the other group receives a placebo. Placebo looks like BI 765423 but does not contain any study medicine. The study medicine is given as an infusion into a vein every four weeks. Participants are in the study for 8-10 months. During the study, participants may continue their regular treatment for IPF. During the study they visit the study site several times for screening, treatment, and follow-up. Doctors regularly test lung function by measuring FVC and take blood samples to measure study endpoints. The results are compared between the two groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.

Начало: 13.11.2025 Край: 02.09.2027 Възраст: от 40 г. Лечение

Australia, Belgium, Canada +7 Boehringer Ingelheim NCT07036523

Набира участници Фаза 2

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay. Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 2 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. Approximately 320 participants will be enrolled in the study at 100 sites around the world. Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused Bev alone. The total study duration will be approximately 40 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Начало: 13.11.2025 Край: 01.01.2029 Възраст: от 18 г. Лечение

Australia, South Korea AbbVie NCT07059845

Набира участници Ранна Фаза 1

Oral Carnitine in Heart Failure Patients

Heart Failure Carnitine Deficiency

Heart failure is a condition in which the heart is unable to pump blood effectively, leading to symptoms like being more tired, shortness of breath, and swelling in the body. Carnitine is a naturally occurring substance in the body that plays a role in turning fat into energy. This study will determine whether oral L-Carnitine supplementation can improve symptoms, enhance heart function and possibly improve the quality of life in individuals with heart failure.

Начало: 12.11.2025 Край: 31.12.2026 Възраст: от 18 г.

Canada London Health Sciences Centre Research Institute OR Law NCT07201714

Набира участници

AI-Assisted Chemotherapy Side Effect Management

Breast Cancer Colorectal Cancer

This two-stage adaptive randomized controlled trial evaluates the feasibility and preliminary efficacy of large language model (LLM)-assisted intervention for managing chemotherapy side effects in patients with solid tumors. Adults with histologically confirmed breast or colorectal cancer scheduled for at least 3 months of systemic chemotherapy will be randomly assigned (1:1) to receive either LLM-assisted care or standard care. The study employs an adaptive design with initial enrollment of 60 patients (30 per arm), followed by interim analysis. Unless enrollment is stopped for safety reasons identified at interim analysis, an additional 114 patients will be enrolled for a maximum total of 174 patients (87 per arm). In the intervention group, healthcare providers input anonymized patient symptom data into an LLM system using sessions where data is not retained, which generates evidence-based management recommendations. Physicians critically review these recommendations and use them as reference for clinical decision-making, with final treatment decisions remaining under physician discretion. The control group receives standard supportive care without LLM assistance. The primary outcome is change in health-related quality of life measured by EORTC QLQ-C30 global health status/QoL scale from baseline to end of treatment. Secondary outcomes include proportion achieving clinically meaningful improvement (≥8-point increase), treatment adherence, dose intensity, healthcare resource utilization, and physician acceptance of LLM recommendations.

Начало: 12.11.2025 Край: 31.10.2026 Възраст: от 18 г.

South Korea Incheon St.Mary's Hospital NCT07198581

Набира участници

Study on the Effects of Drugs That Modulate the Endocannabinoid System on Spontaneous and Induced Contractility of the Human Detrusor Muscle

Bladder Cancer

The goal of this observational, in vitro study is to evaluate the effects of drugs that modulate the endocannabinoid system on spontaneous and neuronally induced contractility of the human detrusor. The study will include adult patients undergoing elective radical cystectomy for bladder cancer. The main questions it aims to answer are whether modulation of endocannabinoid receptors, enzymes involved in endocannabinoid synthesis and degradation, and endocannabinoid transport mechanisms alters basal detrusor contractility and modifies excitatory motor responses induced by neuronal activation. Participants undergoing radical cystectomy will provide written informed consent for the collection of a small sample of macroscopically healthy bladder tissue from the surgical specimen. Detrusor muscle strips will be prepared and studied in vitro using organ bath techniques. Contractile activity will be recorded under baseline conditions and after electrical field stimulation, as well as following exposure to pharmacological modulators of the endocannabinoid system. Demographic, clinical, and pathological data will also be collected for descriptive analysis.

Начало: 12.11.2025 Край: 01.05.2028 Възраст: от 18 г.

Italy Fondazione Policlinico Universitario Agostino Gemelli I NCT07545694

Набира участници

RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative

Cannabis Use Disorder

The purpose of this sham-controlled pilot randomized controlled trial (RCT) is to evaluate the feasibility, safety, and preliminary efficacy of a one-month intervention consisting of 20 home-based active or sham RS-tDCS sessions paired with audio track guided mindfulness meditation practice in otherwise healthy adults seeking to reduce cannabis use in the context of cannabis use disorder (CUD).

Начало: 12.11.2025 Край: 01.10.2026 Възраст: 22–65 г.

United States NYU Langone Health NCT07184983

Набира участници

Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects

Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma

To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.

Начало: 12.11.2025 Край: 15.08.2028

Australia Aura Biosciences NCT07421739

Набира участници

Nourishing Tomorrow: Role of Medically Tailored Groceries in Addressing Food Insecurity During Pregnancy

Pregnancy Related Prematurity Birth Outcome, Adverse

Medically tailored groceries (MTG), involving grocery items to be prepared at home, selected by a nutritional professional based on a treatment plan, is a growing approach adopted by healthcare systems to address food insecurity in their patient populations, a leading contribution to health disparities such as poor birth outcomes within pregnant populations. However, transportation and other social needs can often hinder patient uptake of clinic-based approaches. Findings from this study will help to better understand how home delivery of MTGs, with and without supplemental education and support to improve food literacy, behavioral and health outcomes.

Начало: 12.11.2025 Край: 31.05.2029 Възраст: 18–55 г.

United States Case Western Reserve University NCT06965530

Набира участници Фаза 3

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

Alzheimers Disease

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).

Начало: 12.11.2025 Край: 07.06.2028 Възраст: 50–90 г. Лечение

Argentina, Australia, Brazil +12 Hoffmann-La Roche NCT07170150

Набира участници Фаза 2

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Ovarian Cancer

This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

Начало: 12.11.2025 Край: 24.10.2027 Възраст: 18–99 г. Лечение

Australia, Belgium, Japan +5 Incyte Corporation NCT07023627

Набира участници Фаза 1/2

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).

Начало: 12.11.2025 Край: 03.07.2028 Възраст: от 12 г. Лечение

Australia, Canada, China +6 AstraZeneca NCT07109219

Набира участници Фаза 2

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Cervical Cancer HPV-Related Carcinoma HPV-Related Malignancy Recurrent Cervical Carcinoma +1

This Phase 2 study will evaluate the efficacy and safety of PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.

Начало: 11.11.2025 Край: 30.11.2030 Възраст: от 18 г.

United States Precigen, Inc NCT06157151

Набира участници Фаза 3

A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)

Hyperlipidemia

Researchers designed a study medicine called enlicitide to lower low-density lipoprotein cholesterol (LDL-C). In this study, researchers want to learn about giving enlicitide with another medicine called rosuvastatin. Rosuvastatin is a standard (usual) treatment to lower LDL-C. The goal of this study is to learn if enlicitide given with rosuvastatin works better than placebo on lowering LDL-C in a person's blood. A placebo looks like the study medicine but has no study medicine in it. Using a placebo helps researchers better understand the effects of a study medicine.

Начало: 11.11.2025 Край: 01.03.2027 Възраст: 18–64 г. Лечение

Argentina, Australia, Brazil +8 Merck Sharp & Dohme LLC NCT07216482

Набира участници Фаза 3

AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL

Large B-cell Lymphoma

The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

Начало: 11.11.2025 Край: 28.07.2033 Възраст: 65–130 г. Лечение

Australia, Belgium, Brazil +8 AstraZeneca NCT07215585

Набира участници Фаза 3

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Secondary Progressive Multiple Sclerosis (SPMS)

The purpose of this study is to provide efficacy and safety data for remibrutinib in patients with secondary progressive multiple sclerosis (SPMS)

Начало: 11.11.2025 Край: 02.01.2034 Възраст: 18–65 г. Лечение

Argentina, Australia, Austria +21 Novartis Pharmaceuticals NCT07225504

Набира участници

Early Phase Study Using the 'Pivot Extend' System as a Treatment for Patients With Tricuspid Regurgitation

Tricuspid Regurgitation

Participants with severe tricuspid regurgitation may require heart surgery to repair or replace the tricuspid valve. However, there is a high risk associated with these surgeries and it is often not feasible for elderly patients or those with other medical conditions. The goal of this clinical investigation is * To assess the safety of the investigational device "Pivot Extend" in participants aged 18 years or over with severe and clinically symptomatic Tricuspid Regurgitation (TR) deemed suitable for percutaneous valve intervention * To evaluate device success, procedural success and clinical outcomes in improving TR symptoms following implantation of the "Pivot Extend" device

Начало: 11.11.2025 Край: 01.03.2027 Възраст: от 18 г. Лечение

Australia Tau Medical Australia Pty Ltd NCT07172477

Набира участници Фаза 1

A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors

Solid Tumors Advanced Solid Tumor

This study is a first-in-human (FIH), Phase 1a/1b study of BG-C0902, a fully humanized anti-epidermal growth factor receptor (EGFR) and anti-mesenchymal-epithelial transition (MET) antibody, conjugated via an enzymatically cleavable linker to a topoisomerase 1 (TOPO1) inhibitor payload. The study aims to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C0902 in participants with advanced solid tumors. The study will be conducted in 2 phases: Phase 1a (dose escalation and safety expansion) and Phase 1b (dose expansion).

Начало: 10.11.2025 Край: 01.11.2027 Възраст: от 18 г. Лечение

Australia, China, United States BeOne Medicines NCT07181681

Набира участници

A Randomized Controlled Trial Evaluating the Feasibility and Preliminary Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Advanced Epithelial Ovarian Cancer

Ovarian Cancer

Evaluation Compared with traditional NACT, whether PIPAC can increase the incidence of CRS3 determines the rationality of choosing PIPAC.

Начало: 10.11.2025 Край: 10.11.2027 Възраст: 18–70 г.

China tongweihua NCT07544030

Набира участници Фаза 2

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Geographic Atrophy Secondary to Age-related Macular Degeneration

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Начало: 10.11.2025 Край: 30.08.2030 Възраст: от 60 г. Лечение

Australia, Canada, United States ADARx Pharmaceuticals, Inc. NCT06990269

1 … 60 61 62 63 64 … 222